An oncology test is any medical test used to detect, diagnose, stage, or monitor cancer. There isn’t a single “oncology test.” The term covers a wide range of procedures, from routine blood draws and imaging scans to tissue biopsies and advanced genetic sequencing. Some oncology tests screen for cancer before symptoms appear, others confirm a diagnosis, and still others help doctors choose the right treatment or track whether it’s working.
Screening Tests: Catching Cancer Early
Screening tests look for signs of cancer in people who feel perfectly healthy. The goal is early detection, when treatment is most effective. The most common screening tests follow age-based guidelines from organizations like the American Cancer Society:
- Mammograms for breast cancer, recommended annually starting at age 45 (with the option to begin at 40). Women 55 and older can switch to every two years.
- Colonoscopies and stool-based tests for colorectal cancer, starting at age 45 for people at average risk.
- Pap tests for cervical cancer, starting at age 25 and continuing until at least 65.
A positive screening result doesn’t mean you have cancer. It means something looks abnormal enough to warrant further testing. That next step is diagnostic testing.
Imaging Tests: Seeing Inside the Body
Imaging scans give doctors a picture of what’s happening inside your body without surgery. Different types reveal different information, and you may need more than one.
A CT scan (computed tomography) provides detailed structural images. It’s especially good at measuring tumor size, pinpointing a tumor’s location, and detecting whether cancer has invaded bone. CT is often the first imaging test ordered when cancer is suspected.
MRI (magnetic resonance imaging) excels at distinguishing between different types of soft tissue. It’s the preferred method for spotting cancer that has spread to the brain, invaded bone marrow, or grown along nerve pathways. For prostate cancer, a specialized MRI is the standard for local staging.
PET scans detect metabolic activity rather than structure. Cancer cells burn through energy faster than normal cells, so they light up on a PET scan. This makes PET particularly useful for finding cancer that has spread to lymph nodes or distant organs. In non-small cell lung cancer, PET scans detect previously unsuspected metastases in up to 28% of patients, changing the treatment plan in over half of cases. PET and CT are often combined into a single PET/CT scan that shows both where a tumor is and how active it is.
Biopsies: Confirming the Diagnosis
Imaging can suggest cancer, but in most cases, a biopsy is the only way to confirm it. A biopsy removes a small sample of tissue so a pathologist can examine the cells under a microscope. The type of biopsy depends on where the suspicious area is located.
A needle biopsy is the most common. A doctor inserts a thin needle into a lump you can feel through the skin, like a breast mass or swollen lymph node, and withdraws a small tissue sample. When the suspicious area is deeper inside the body (the liver, lung, or prostate, for example), the needle is guided by imaging such as ultrasound or CT.
Endoscopic biopsies collect tissue from inside hollow organs. A thin, flexible tube with a camera is threaded into the body through a natural opening. A colonoscopy samples tissue from the colon, a bronchoscopy from the lungs, and a cystoscopy from the bladder.
Bone marrow biopsies diagnose blood cancers like leukemia, lymphoma, and multiple myeloma. A needle is inserted into the hip bone to withdraw a small core of marrow. Surgical biopsies, where a doctor removes part or all of a suspicious mass through an incision, are reserved for cases where other biopsy methods can’t reach the area or have come back inconclusive.
What Happens After a Biopsy: Pathology Results
Once tissue is collected, it goes to a pathology lab. A pathologist examines the cells, determines whether they’re cancerous, and if so, identifies the type of cancer and how abnormal the cells look (the grade). Higher-grade cancers tend to grow and spread more quickly.
The standard benchmark for pathology turnaround is two business days for routine cases, set by the College of American Pathologists. In practice, about 1 in 4 routine cases takes longer than that. Complex cases that require additional staining or specialist review can take a week or more. Waiting for results is one of the most stressful parts of the process, so it helps to ask your doctor upfront what timeline to expect.
Staging: Determining How Far Cancer Has Spread
If cancer is confirmed, the next step is staging. Staging tells you and your doctors how large the tumor is and whether it has spread. Most solid cancers use the TNM system: T describes the size of the primary tumor, N indicates whether nearby lymph nodes are involved, and M records whether cancer has metastasized to distant parts of the body.
No single test determines the stage. Staging pulls together results from imaging (CT, MRI, PET), biopsies, blood work, and sometimes endoscopy or minimally invasive surgical procedures. For lung cancer, a baseline CT of the chest and abdomen plus a PET/CT scan is the standard combination before treatment begins. Brain MRI is added when there’s concern about metastasis to the central nervous system. Each piece of information fills in a different part of the picture.
Blood Tests and Tumor Markers
Certain blood tests measure proteins or other substances that cancer cells produce in unusually high amounts. These are called tumor markers. They’re rarely used to diagnose cancer on their own, but they play important roles in monitoring treatment and watching for recurrence.
PSA (prostate-specific antigen) helps in diagnosing prostate cancer and tracking whether it returns after treatment. CA 19-9 is used to assess whether treatment is working for pancreatic and bile duct cancers. Alpha-fetoprotein (AFP) helps diagnose and monitor liver cancer and certain ovarian and germ cell tumors. Your doctor might check these markers repeatedly over months or years. A rising level can be an early signal that cancer is growing or coming back, sometimes before it shows up on a scan.
Genetic and Genomic Testing
Modern oncology increasingly relies on tests that analyze the DNA of a tumor. These tests look for specific genetic mutations that drive a cancer’s growth, which can directly determine which treatments will work best for you.
Comprehensive genomic profiling examines hundreds of genes in a single test, using a technology called next-generation sequencing. The results can identify mutations that make a tumor vulnerable to targeted therapies. In non-small cell lung cancer, for instance, mutations in the EGFR gene can be targeted with specific drugs that produce significantly better outcomes than standard chemotherapy. Without testing, those mutations would go undetected and the most effective treatment would be missed.
These genomic tests typically take two to four weeks for results because of the complexity of the analysis. The tissue used often comes from the same biopsy sample that was already collected, so a second procedure isn’t always necessary.
Liquid Biopsies: Testing Through a Blood Draw
A liquid biopsy is a newer approach that detects fragments of tumor DNA circulating in the bloodstream. When cancer cells die, they release small pieces of their DNA into the blood. A liquid biopsy captures and analyzes those fragments, providing genetic information about the tumor without the need for a tissue biopsy.
This is especially valuable when a tumor is in a location that’s difficult or risky to biopsy, or when doctors need to monitor how a cancer’s genetic profile changes over time. Because it only requires a standard blood draw, it can be repeated easily. Liquid biopsies are currently used most often for patients with advanced cancer to guide treatment decisions or detect recurrence early.
A related development is multi-cancer early detection (MCED) tests, which aim to screen for dozens of cancer types from a single blood sample. A few are already available, though they’re still being refined. One Mayo Clinic study found that 1 in 4 positive MCED results turned out to be a false positive, which means a positive result requires follow-up testing before drawing conclusions.
How These Tests Work Together
Oncology testing is rarely a single event. It’s a sequence. A screening test flags something abnormal. Imaging narrows down the location and size. A biopsy confirms whether it’s cancer and what type. Staging tests map how far it has spread. Genomic testing identifies which treatments are most likely to succeed. And after treatment begins, blood tests, imaging, and sometimes repeat biopsies track how well it’s working.
Each test answers a different question, and together they build the full picture that guides every treatment decision. The specific tests you’ll encounter depend on the type of cancer suspected, where it is in the body, and how far along the diagnostic process you are.